Sugi Predict

Sugi Predict / Compounds / SCHEMBL631424

SCHEMBL631424

SCHEMBL631424

CC(C)(C)[Si](C)(C)OCc1cccc(N)c1

nearest known ligand 0.42

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
▸ MAOB P27338 3/20 0.42
▸ MAOA P21397 2/20 0.42
▸ CYP19A1 P11511 1/20 0.41
▸ CYP2D6 P10635 1/20 0.40
▸ MRGPRX4 Q96LA9 1/20 0.40
▸ IDO1 P14902 7/20 0.40
▸ ACHE P22303 1/20 0.39
▸ ABHD6 Q9BV23 1/20 0.39
▸ AGXT P21549 4/20 0.38
▸ CYP11B1 P15538 1/20 0.36
▸ CYP11B2 P19099 1/20 0.36
▸ TP53 P04637 1/20 0.36
▸ CYP3A4 P08684 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4380251 0.83 ENPP2 (0.43) MAOBMRGPRX4IDO1AGXTCYP3A4
SCHEMBL18924077 0.82 DUT (0.32) —
SCHEMBL4083198 0.82 GRM2 (0.41) MAOBMAOAACHE
SCHEMBL840465 0.81 GABRA1 (0.45) ACHECYP3A4
SCHEMBL11942311 0.81 IDO1 (0.38) IDO1AGXTTP53CYP3A4
SCHEMBL5280684 0.80 MAOB (0.44) MAOBMAOACYP19A1IDO1ABHD6
SCHEMBL501378 0.80 MRGPRX4 (0.41) MAOBMRGPRX4IDO1CYP11B1CYP11B2
SCHEMBL21367138 0.80 CYP3A4 (0.56) MAOBMAOAIDO1AGXTCYP3A4
SCHEMBL15687564 0.80 IDO1 (0.36) IDO1AGXTCYP3A4
SCHEMBL722684 0.80 IDO1 (0.56) MAOBMAOAIDO1AGXT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 97 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES INC (US) 2025-11-27 — — US disclosed
WO-2025001407-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUNDS AND USES THEREOF 浙江养生堂天然药物研究所有限公司 2025-01-02 — — WO disclosed
CN-119192199-A Polyaryl-containing macrocyclic compounds and uses thereof 浙江养生堂天然药物研究所有限公司 2024-12-27 — — CN disclosed
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS GILEAD SCIENCES, INC. 2024-12-05 — — US disclosed
EP-4445902-A2 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS Carna Biosciences, Inc. (JP) 2024-10-16 — — EP disclosed
WO-2024199069-A1 POLYARYL-CONTAINING MACROCYCLIC COMPOUND AND USE THEREOF 浙江养生堂天然药物研究所有限公司 2024-10-03 — — WO disclosed
CN-118724916-A Polyaryl-containing macrocyclic compounds and uses thereof 浙江养生堂天然药物研究所有限公司 2024-10-01 — — CN disclosed
EP-4081305-B1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS CARNA BIOSCIENCES INC (JP) 2024-09-18 — — EP disclosed
US-12054490-B2 Diacylglycerol kinase modulating compounds GILEAD SCIENCES, INC. (US) 2024-08-06 — — US disclosed
CN-118324767-A Diacylglycerol kinase modulating compounds 卡尔那生物科学株式会社 2024-07-12 — — CN disclosed
WO-2008046757-A1 AMINOMETHYL-4-IMIDAZOLES F. HOFFMANN-LA ROCHE AG (CH) 2008-04-24 — — WO disclosed
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2007-06-14 — — US disclosed
US-6541480-B2 Controlling cytokines SUNTORY LIMITED (JP) 2003-04-01 — — US disclosed
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor DAIICHI ASUBIO PHARMA CO., LTD. (JP) 2002-01-17 — — US disclosed
US-6297248-B1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor SUNTORY LIMITED (JP) 2001-10-02 — — US disclosed
EP-0958297-A1 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR SUNTORY LIMITED (JP) 1999-11-24 — — EP disclosed
WO-1999007704-A1 1-ARYL-1,8-NAPHTHYLIDIN-4-ONE DERIVATIVE AS TYPE IV PHOSPHODIESTERASE INHIBITOR SUNTORY LIMITED (JP) 1999-02-18 — — WO disclosed
US-5484786-A ANTIALLERGENS, ANTIINFLAMMATORY AGENTS ABBOTT LABORATORIES (US) 1996-01-16 — — US disclosed
US-5432194-A Antiallergens, antinflammatory agents ABBOTT LABORATORIES (US) 1995-07-11 — — US disclosed
US-5346914-A Antiallergens, antiinflammatory agents ABBOTT LABORATORIES (US) 1994-09-13 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240400568-A1 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK MAOB 3357/4885MAOA 4176/4885CYP19A1 3959/4885
US-20070135452-A1 Nitrogen-containing fused heterocyclic compounds NPY4R, NR4A3, NR3C2 MAOB 386/4885MAOA 441/4885CYP19A1 417/4885
US-12054490-B2 Diacylglycerol kinase modulating compounds DGKG, DGKB, DGKK MAOB 3357/4885MAOA 4176/4885CYP19A1 3959/4885
US-20250361236-A9 DIACYLGLYCEROL KINASE MODULATING COMPOUNDS DGKG, DGKB, DGKK MAOB 3357/4885MAOA 4176/4885CYP19A1 3959/4885
US-20020006935-A1 1-aryl-1,8-naphthylidin-4-one derivative as type IV phosphodiesterase inhibitor PDE3A, PDE5A, PDE3B MAOB 178/4885MAOA 113/4885CYP19A1 246/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.